Intestinal resection-associated metabolic syndrome.

Area of Science:

• Metabolic disorders
• Pediatric diseases
• Surgical outcomes

Background:

• Short bowel syndrome (SBS) is a life-threatening pediatric condition resulting from massive small bowel resection (SBR).
• Previous studies in a murine SBR model revealed hepatic steatosis, gut dysbiosis, and increased fat deposition.
• These findings necessitated an investigation into glucose metabolism and systemic inflammation post-intestinal resection.

Purpose of the Study:

• To investigate the metabolic consequences of massive small bowel resection (SBR) in a murine model.
• To assess alterations in glucose metabolism and systemic inflammation following SBR.
• To determine if SBR leads to a novel metabolic syndrome.

Main Methods:

• Male C57BL6 mice underwent 50% proximal small bowel resection (SBR) or sham operation.
• Evaluated body weight, body composition, fasting blood glucose (FBG), and performed glucose and insulin tolerance tests.
• Analyzed small bowel, pancreas, and serum samples post-sacrifice.

Main Results:

• SBR mice exhibited reduced weight gain and significantly higher FBG compared to sham controls after 10 weeks.
• Resected mice showed altered body composition, elevated blood glucose, increased pancreatic islet area, and heightened systemic inflammation.
• No significant alteration in insulin tolerance was observed post-resection.

Conclusions:

• Massive small bowel resection (SBR) induces abnormal body composition, glucose metabolism, and systemic inflammation.
• These metabolic derangements, alongside hepatic steatosis, suggest a novel resection-associated metabolic syndrome.
• The findings highlight significant metabolic consequences of SBR, independent of parenteral nutrition.